Key result
High IL-6 and IL-1β linked to adverse CV events and potential risk reduction if lowered.
Why the study?
Interleukins play critical roles in cardiovascular disease pathogenesis and represent key therapeutic targets and biomarkers, warranting a detailed overview of their involvement.
Interleukins, particularly IL-6 and IL-1β, play a crucial role in cardiovascular disease pathogenesis and represent promising therapeutic targets and biomarkers for cardioprotection.
IL-6/IL-1β inhibition merits targeted trials in atherosclerosis; leaves open whether benefits exceed current therapies.
Interleukins are important inflammatory cytokines involved in cardiovascular (CV) disease (CVD) pathogenesis, particularly in atherosclerosis, by regulating inflammation, endothelial dysfunction, plaque formation, thrombosis, immune responses, and hematopoiesis. High levels of interleukin (IL)-6 and IL-1β are strongly associated with plaque progression, adverse CV events, peripheral artery disease, heart failure, and mortality, rendering them key therapeutic targets. Lowering IL-6 activity shows promising potential to reduce CV risk without raising the risk of infection. These molecules also seem to have a role in hypertension, cardiac arrhythmias, and stroke. They can be useful biomarkers for CVD and also targets for the development of cardioprotective therapies. Their inhibitors have important protective influences in CVD. All these issues are herein detailed and pictorially illustrated.
No takes yet. Share an insight, caveat, or question.
Manolis et al. (2026) conducted a review in Cardiovascular disease. Interleukins (IL-6 and IL-1β) was evaluated. High levels of interleukins, particularly IL-6 and IL-1β, are strongly associated with adverse cardiovascular events, and lowering their activity shows potential to reduce cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: